2024 Volume 59 Issue 2 Pages 107-112
The incidence of de novo malignancy after heart transplantation is increasing due to the need for immunosuppressive therapy for life. Development of malignancy is one of the severe problems which affects transplant outcome and in fact, previous studies reported the marked decrease in survival rates. Skin, prostate, lung or breast cancers are reported to increase in adult recipients and post-transplant lymphoproliferative disorder is increasing in pediatric recipients. Not only male or older recipients, but also recipient with a history of malignancy or Epstein-Barr virus status are reported to face risk of de novo malignancies after heart transplantation. As a result, we need to plan systematically for recipients before transplantation. Further study on specific screening and treatment methods for early detection and treatment of malignancies after heart transplantation is needed.
